Loading stock data…
Ionis Pharmaceuticals (IONS)
$80.69-0.49 (-0.60%)
Market ClosedLast close Jun 29
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ionis Pharmaceuticals, Inc. in the Healthcare sector is trading at $80.69 with a market capitalization of $12.0B. Wall Street consensus targets $105.91 (23 analysts), implying a +31.3% move over the next 12 months. The stock is currently near its 52-week high of $86.74, remaining 6.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $246.09M↑ | $203.33M↑ | $156.72M↓ | $452.05M↑ | $131.61M |
| Gross Profit | $243.09M↑ | $195.37M↑ | $154.38M↓ | $447.90M↑ | $130.11M |
| Operating Income | -$117.48M↑ | -$214.47M↓ | -$160.17M↓ | $139.84M↑ | -$146.95M |
| Net Income | -$92.53M↑ | -$229.39M↓ | -$128.61M↓ | $123.55M↑ | -$146.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.54%
Volume
Today's trading volume
2.52M
Recent News
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S.
Ionis Pharmaceuticals (NasdaqGS:IONS) has signed an ex U.S. licensing agreement with Recordati for zilganersen, an investigational RNA therapy for Alexander disease. The deal grants Recordati rights to commercialize zilganersen outside the U.S., while Ionis retains U.S. rights and global development leadership. Ionis is set to receive upfront and milestone payments, plus potential royalties on ex U.S. sales, as FDA review of zilganersen for Alexander disease continues. Ionis Pharmaceuticals...
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia
Earlier this week, Ionis Pharmaceuticals reported that the FDA approved Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, expanding its use beyond familial chylomicronemia syndrome. This approval makes Tryngolza the first and only therapy in the US with a label specifically addressing both triglyceride reduction and acute pancreatitis risk in this high‑need population, potentially reshaping care standards in severe...
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Ionis grants Recordati rights to zilganersen for Alexander disease
Recordati will handle regulatory filings and commercial operations ex-US, including supporting early access initiatives.
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.